Posts

Recent Biotech Reverse Mergers Accelerate BTK‑Based Immune & Inflammatory Drug Programs

on

Caldera snaps up Synlogic in reverse merger to hit Nasdaq and fund IBD pipeline through 2029

on

Yarrow begins trading as it advances Graves’ disease and thyroid eye disease program

on

Remix to take Nasdaq listing from Passage Bio in reverse merger for mRNA degrader platform

on

Serapha Bio takes flight from Boundless merger with $230M and gene-editing prospect from China

on

Boundless Bio agrees to reverse merger with Serapha Bio in $230M gene‑editing deal

on

Treeline to go public via reverse merger with Standard BioTools

on

After being ditched by Candid, Rallybio finds Avenzo to take its Nasdaq listing

on

Obsidian Therapeutics Goes Public Through Galera Reverse Merger with $350M PIPE Financing

on

Korsana Biosciences Goes Public Through Reverse Merger with Cyclerion Therapeutics

on

Barinthus Biotherapeutics Announces Reverse Merger with Clywedog Therapeutics to Form New Metabolic Disease-Focused Company

on